PDSBHealthcare · BiotechnologyThe 2 Wall Street analysts covering PDS Biotechnology Corp. hold a median 12-month price target of $4.5 — +246.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 82 of 100 as at 4 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores PDS Biotechnology Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (94): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (9): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PDSB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +246.2% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | B. Riley Securities | Reiterates | Buy | $3.00 → $4.00 |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $5.00 |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 26 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $7.00 |
| 13 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 15 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 25 Nov 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 11 June 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 27 Mar 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Nov 2024 | B. Riley Securities | Maintains | Buy | — |
| 15 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PDSB appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, PDS Biotechnology Corp. returned +46.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 86% of US stocks
Cheaper than 98% of US stocks
Cheaper than 76% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 3% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
PDS Biotechnology Corp. has a market value of $146.5M and an enterprise value of $75.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$33.7M.
Free cash flow in the twelve months to 30 June 2026: −$16.8M.
Trailing P/E: −1.9×; forward P/E: −7.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
PDS Biotechnology Corp. employs 21 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own PDS Biotechnology Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
PDS Biotechnology reached a technical support level, and its 50-day simple moving average recently crossed above its 200-day moving average, a pattern known as a golden cross.
Why it matters — PDSB watchers may note the reported moving-average crossover as a technical signal.
PDS Biotechnology appointed John Dawson CBE, Deborah Ramsdell and Bruce Wendel to its Board of Directors, citing their corporate development, commercialization and regulatory experience. The company is advancing PDS0301 toward a Phase 3 trial in metastatic colorectal cancer and PDS0101 toward potential partnerships.
Why it matters — The appointments add industry experience to the board as PDS Biotechnology pursues these stated development and partnership goals.
PDS Biotechnology outlined plans to advance investigational immunocytokine PDS0301 into a Phase III study for heavily pretreated metastatic colorectal cancer with liver metastases. The plans follow discussions with the FDA and clinical findings from a National Cancer Institute-led study.
Why it matters — The proposed Phase III study marks a planned next step for PDS0301 in this cancer setting.
Seeking Alpha published a transcript discussing PDS Biotechnology Corporation’s PDS-0301 immunocytokine and its role in treating metastatic colorectal cancer.
Why it matters — The transcript concerns a PDSB drug candidate and its potential role in treating metastatic colorectal cancer.
PDS Biotechnology was upgraded to Zacks Rank #2 (Buy), reflecting growing optimism about its earnings prospects. The excerpt says this might drive the stock higher in the near term.
Why it matters — PDSB watchers may note the upgrade as a signal of increased optimism about the company’s earnings prospects.
The 2 Wall Street analysts covering PDS Biotechnology Corp. have a median 12-month price target of $4.5, with estimates ranging from $4 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 2 analysts covering PDS Biotechnology Corp., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks PDS Biotechnology Corp. 82 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 4 Nov 2026, PDS Biotechnology Corp. ranks 82 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (94 of 100).
No one can know that. What the data says: the median 12-month target from 2 analysts implies +246.2% from the last close, and Ticker Nerd's factor model ranks PDS Biotechnology Corp. 82 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering PDS Biotechnology Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PDSB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $5 over the next 12 months.
PDS Biotechnology Corp. returned +46.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications.
The most recent item we track (Zacks Investment Research, 4 Nov 2026): "PDS Biotechnology (PDSB) Just Flashed Golden Cross Signal: Do You Buy?". PDS Biotechnology reached a technical support level, and its 50-day simple moving average recently crossed above its 200-day moving average, a pattern known as a golden cross.
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing immunotherapies that harness T cells to target cancer. Its current pipeline centers on the Versamune platform, which is designed to stimulate and direct immune responses against tumors, with programs spanning multiple oncology indications. The company also works on tumor-targeted approaches that combine immune activation with precision delivery, supporting research across head and neck, cervical, prostate, anal, breast, and other cancers. PDS Biotechnology Corporation operates as a specialist in immuno-oncology, aiming to address areas where conventional treatments may be limited. Based in Princeton, New Jersey, the company focuses on advancing current product candidates through clinical development and commercialization efforts in the biopharmaceutical market.
CEO Dr. Frank K. Bedu-Addo Ph.D. · 21 employees · United States · https://www.pdsbiotech.com
